Take Homes from Miami Breast Cancer Conference: Targeted Therapies

In this video, Debu Tripathy, MD, discussed developments in HER2-positive breast cancer targeted treatments, including antibody-drug conjugates, which were reviewed at 39th Miami Breast Cancer Conference.

In this video, Debu Tripathy, MD, discussed the role of oral selective estrogen receptor down regulators in treating breast cancer patients with ESR1 mutations.

In this video, Sara Hurvitz, MD, discussed her presentation at 39th Miami Breast Cancer Conference.on strategies and tactics clinicians can use to de-escalate side effects for patients being treated for HER2-positive breast cancer.

In this video, Sara Hurvitz, MD, discussed the "practice changing" data from the KEYNOTE-522 phase 3 trial reviewed at 39th Miami Breast Cancer Conference.

In this video, Sara Hurvitz, MD, discussed recent developments in oral selective estrogen degraders reviewed at 39th Miami Breast Cancer Conference.

In this video, Kevin Kalinsky, MD, discussed the approval of single agent pembrolizumab, which is agnostic to tumor histology the role of ARP inhibitors for patients with BRCA mutations.

In this video, Kevin Kalinsky, MD, discussed recent developments in the treatment of metastatic triple-negative breast cancer presented at 39th Miami Breast Cancer Conference.

In this video, Kevin Kalinsky, MD, an associate professor of medicine at New York-Presbyterian Hospital/Columbia University Medical Center, discussed the Destiny 04 Trial presented at 39th Miami Breast Cancer Conference.

In this video, Kevin Kalinsky, MD, discussed new data on antibody-drug conjugates, including sacituzumab, presented at 39th Miami Breast Cancer Conference.

In this video, Patrick Borgen, MD, chair of the department of surgery at Maimonides Medical Center, discussed the potential of using oral selective estrogen receptor degraders, or SERDs, in breast cancer at the 38th Annual Miami Breast Cancer Conference.